Patents by Inventor Matthew J. Wyvratt, Jr.

Matthew J. Wyvratt, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6162813
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related conditions in both men and women.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: December 19, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Robert J. Devita, Matthew J. Wyvratt, Jr., Jonathan R. Young
  • Patent number: 6156767
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: December 5, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Matthew J. Wyvratt, Jr., Peter Lin, Lin Chu, Narindar N. Girotra
  • Patent number: 6156772
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: December 5, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Thomas F. Walsh, Feroze Ujjainwalla, Matthew J. Wyvratt, Jr.
  • Patent number: 6150522
    Abstract: There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related conditions in both men and women.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: November 21, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Robert J. DeVita, Matthew J. Wyvratt, Jr., Jonathan R. Young
  • Patent number: 6150352
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related conditions in both men and women.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: November 21, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Eric E Allen, Matthew J. Wyvratt, Jr., Jinlong Jiang, Richard B. Toupence, Thomas F Walsh, Feroze Ujjainwalla, Jonathan R Young, Robert J. Devita
  • Patent number: 6147088
    Abstract: There are disclosed compounds of formula (I) and pharmaceutical acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related conditions.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: November 14, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Eric E Allen, Matthew J. Wyvratt, Jr., Jinlong Jiang, Roy G. Smith, Thomas F Walsh, Yi Tien Yang, Jonathan R Young, Robert J. Devita
  • Patent number: 6077858
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: September 21, 1999
    Date of Patent: June 20, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Feroze Ujjainwalla, Thomas F. Walsh, Matthew J. Wyvratt, Jr., Jonathan R. Young, Lin Chu
  • Patent number: 6004984
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: December 21, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Feroze Ujjainwalla, Thomas F. Walsh, Matthew J. Wyvratt, Jr.
  • Patent number: 5985901
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: November 16, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Feroze Ujjainwalla, Thomas F. Walsh, Matthew J. Wyvratt, Jr., Jonathan R. Young, Lin Chu
  • Patent number: 5981550
    Abstract: There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: November 9, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Mark Goulet, Thomas F. Walsh, Feroze Ujjainwalla, Matthew J. Wyvratt, Jr., Jonathan R. Young, Lin Chu
  • Patent number: 5545735
    Abstract: There are disclosed certain novel compounds identified as benzo-fused lactams which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to increase the stature of those afflicted with a lack of a normal secretion of natural growth hormone. Growth promoting compositions containing such benzo-fused lactams as the active ingredient thereof are also disclosed.
    Type: Grant
    Filed: October 4, 1993
    Date of Patent: August 13, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Richard J. Bochis, Paul J. Hodges, William R. Schoen, Matthew J. Wyvratt, Jr.
  • Patent number: 5438136
    Abstract: There are disclosed certain novel compounds identified as benzo-fused macrocycles which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to increase the stature of those afflicted with a lack of a normal secretion of natural growth hormone. Growth promoting compositions containing such benzo-fused macrocycles as the active ingredient thereof are also disclosed.
    Type: Grant
    Filed: November 2, 1993
    Date of Patent: August 1, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Robert J. Devita, William R. Schoen, Alison J. Frontier, Matthew J. Wyvratt, Jr.
  • Patent number: 5434261
    Abstract: There are disclosed certain novel compounds identified as benzo-fused lactams which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to increase the stature of those afflicted with a lack of a normal secretion of natural growth hormone. Growth promoting compositions containing such benzo-fused lactams as the active ingredient thereof are also disclosed.
    Type: Grant
    Filed: July 26, 1993
    Date of Patent: July 18, 1995
    Assignee: Merck & Co., Inc.
    Inventors: William R. Schoen, Matthew J. Wyvratt, Jr.
  • Patent number: 5430144
    Abstract: There are disclosed certain novel compounds identified as benzo-fused lactams which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to increase the stature of those afflicted with a lack of a normal secretion of natural growth hormone. Growth promoting compositions containing such benzo-fused lactams as the active ingredient thereof are also disclosed.
    Type: Grant
    Filed: July 26, 1993
    Date of Patent: July 4, 1995
    Assignee: Merck & Co., Inc.
    Inventors: William R. Schoen, Matthew J. Wyvratt, Jr., Paul J. Hodges
  • Patent number: 5143918
    Abstract: Novel C-3" and C-4" halogen-substituted macrolides of FK-506 type structural Formula I: ##STR1## are described. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases (such as juvenile-onset diabetes melitus, multiple sclerosis and rheumatoid arthritis), infectious diseases and/or the prevention of rejection of foreign organ transplants, e.g. bone marrow and heart transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses such as: psoriasis, atopical dermatitiis, contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis, Lichen planus, Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasulitides erythemas, cutaneous eosinophilias, Lupus erythematosus or Alopecia areata.
    Type: Grant
    Filed: September 12, 1991
    Date of Patent: September 1, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Richard J. Bochis, Matthew J. Wyvratt, Jr.
  • Patent number: 5068323
    Abstract: Ring-expanded macrolides related to FK-506 have immunosuppressive activity.
    Type: Grant
    Filed: April 10, 1990
    Date of Patent: November 26, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Matthew J. Wyvratt, Jr., Thomas R. Beattie, Hyun Ok, Byron H. Arison, Michael H. Fisher
  • Patent number: 5057608
    Abstract: Ring-expanded, immunosuppressive macrolides, are produced by heating and rearranging FK-506 and related compounds.
    Type: Grant
    Filed: April 10, 1990
    Date of Patent: October 15, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Matthew J. Wyvratt, Jr., Thomas R. Beattie, Hyun O. Ok, Byron H. Arison, Michael H. Fisher
  • Patent number: 5019578
    Abstract: The instant invention concerns certain .alpha.-heterocyclic ethanol amines wherein the amine group is substituted with various alkyl and unsaturated alkyl groups optionally further substituted with hydroxy, or alkoxy groups of the formula: ##STR1## These compounds are useful as growth promotion agents in animals.
    Type: Grant
    Filed: April 9, 1990
    Date of Patent: May 28, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Michael H. Fisher, Matthew J. Wyvratt, Jr.
  • Patent number: 4833168
    Abstract: There are disclosed novel avermectin compounds wherein the glycosyl side chain is substituted with, or replaced by an alkyl ester group in a Reformatsky reaction. The compounds are prepared by reacting an .alpha.-halogenated ester to a 4'-, 4"- or 13-keto-avermectin derivative in the presence of a reducing agent. The avermectin compounds have utility as anti-parasitic agents and compositions for that use are also disclosed. The compounds are also highly potent insecticides against agricultural pests.
    Type: Grant
    Filed: October 3, 1986
    Date of Patent: May 23, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Matthew J. Wyvratt, Jr.
  • Patent number: 4731444
    Abstract: There are disclosed bicyclic lactams and derivatives thereof which are useful as converting enzyme inhibitors and as antihypertensives.
    Type: Grant
    Filed: August 3, 1984
    Date of Patent: March 15, 1988
    Assignee: Merck & Co., Inc.
    Inventors: William H. Parsons, Matthew J. Wyvratt, Jr.